CARE Ratings Confirms Zero Deviation in Grasim Industries' ₹4,000 Crore Rights Issue Utilization
Grasim Industries Ltd · Others (Uncategorized) · 13 Nov 2026, 8:19 pm
CARE Ratings Confirms Zero Deviation in Grasim Industries' ₹4,000 Crore Rights Issue Utilization CARE Ratings' Monitoring Agency Report for the quarter ended 30th Sep'26 confirms zero deviation in Grasim Industries' utilization of its ₹3,999.80 crore rights issue proceeds. Out of ₹3,972.85 crore received, ₹3,971.81 crore has been deployed, including ₹3,000.00 crore fully utilized for debt repayment/prepayment and ₹971.81 crore for general corporate purposes (₹0.70 crore deployed in Q2FY27 for employee expenses). An unutilized balance of ₹0.90 crore remains in the monitoring account net of issue expenses. Post-issue promoter shareholding increased from 42.75% to 45.20%.
Original exchange filing (PDF)
More announcements from Grasim Industries Ltd
- Intimation of schedule of Analysts / Institutional Investor Meet · 18 Nov 2026
- Transcript of Conference Call on the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September 2026 · 17 Nov 2026
- Repayment of Commercial Paper · 17 Nov 2026
- Audio Recording - Earnings Call · 14 Nov 2026
- Presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September 2026 · 13 Nov 2026
- Press Release on the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September 2026 · 13 Nov 2026
- Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September 2026 · 13 Nov 2026
- Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th September 2026 · 13 Nov 2026
